The main goal of this study is to evaluate changes in coagulation (blood clotting) factors
and platelet function in multiple myeloma participants undergoing VELCADE treatment for the
Cardiovascular complications during the treatment of patients with multiple myeloma are not
uncommon, (10%) and the frequency clearly increases with the use of regimens containing
thalidomide in combination with glucocorticosteroids or chemotherapy especially adriamycin.
Even with prophylactic anticoagulation, DVT still occurs in 10% of such patients. The use
of full anticoagulation raises considerable concern of bleeding especially during the post
chemotherapy thrombocytopenic period. We observed no thromboembolic episodes when Velcade
was added to thalidomide and adriamycin containing chemotherapy.
Therefore, we would like to investigate this protective antithrombotic effect of VELCADE in
a malignancy associated with a hypercoagulable state in a group of 10 patients with
Relapsed/Refractory Multiple Myeloma.
- Patients with myeloma who had relapsed after one prior treatment and who have
demonstrated resistance to their last treatment, who are candidate to receive Velcade
and had normal PT and PTT, will be evaluated for inclusion in the present study.
- Previous history of venous thromboembolism, myocardial infarction, stroke, TIA
- Hypercoagulable state (deficit ATIII, Factor V Leiden, deficit protein S, deficit
protein C, prothrombin gene mutation), antiphospholipid syndrome.
- Von Willebrand disease, inherited platelet abnormalities.
- Familiar history of hypercoagulable state.
- Anticoagulant therapy, aspirin, non-steroidal anti-inflammatory drugs, beta blockers,
tricyclic antidepressant, hormone replacement therapy, BCPs, and all other agents
able to interfere with platelet function in the previous two weeks.
- Non-secretory MM, unless the patient has measurable lesions on CT, MRI and/or PET.